search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


FATLOSE 2 trial (Fecal Administration To LOSE insulin resistance).


- candidate number8966
- NTR NumberNTR2705
- ISRCTNISRCTN wordt niet meer aangevraagd.
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR18-jan-2011
- Secondary IDs35474 CCMO
- Public TitleFATLOSE 2 trial (Fecal Administration To LOSE insulin resistance).
- Scientific TitleFATLOSE 2 study ‘Single versus multiple fecal transplants harvested from lean volunteers on lipid and glucose metabolism in subjects with metabolic syndrome'.
- ACRONYMFATLOSE2
- hypothesisRecent research shows that obesity is associated with changed bowel flora composition with a relative abundance of the two dominant bacterial divisions, the Bacteroidetes and the Firmicutes. Interestingly, this specific bacteria associated condition is transmissible: colonization of obese mice with an ‘leanmicrobiota’ results in a significantly greater decrease in total body fat (-30%) than colonization with a ‘obese microbiota’ (+5%). In addition, Bacteroidetes species are decreased and Firmicutes increased in feces of obese people compared to lean people . We recently finished the FATLOSE trial, in which we studied the therapeutic effect of donor feces infusion from screened volunteers after 6 weeks on insulin resistance (hyperisulinemic clamp with stable isotopes) in male patients with metabolic syndrome. We found significant reduction in both periferal and hepatic insulin resistance implicating substantial effects of whole body glucose metabolism. Moreover, we found significant reductions in fasting lipidprofiles after allogenic fecal therapy, which are in line with previously published data suggesting a direct effect between duodenal lipid uptake and glucose production orchestrated by gutmicrobiota driven brain-gut axis. The efficacy of fecal therapy is explained by enhanced production of specific short chain free fatty acid butyrate produced by the infused lean donor feces, which probably restores normal fecal physiology by implantation of missing lean-figure flora components.
- Healt Condition(s) or Problem(s) studiedObesity, Insulin resistance, Gut microbiota, SCFA
- Inclusion criteria1. Male obese subjects with metabolic syndrome (n=45);
2. 21 to 69 years-old;
3. Body mass index (BMI) 30 to 43 kg/m2);
4. At least 3 out of 5 NCEP metabolic syndrome criteria.
- Exclusion criteria1. Cardiovascular event (MI or pacemaker implantation);
2. Use of medication including PPI and antibiotics;
3. (Expected) prolonged compromised immunity (due to recent cytotoxic chemotherapy or HIV infection with a CD4 count < 240).
- mec approval receivedyes
- multicenter trialno
- randomisedyes
- masking/blindingDouble
- controlPlacebo
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 1-mei-2011
- planned closingdate1-nov-2013
- Target number of participants45
- InterventionsPatients will be randomised to one of the three treatment arms:
Single (baseline) or multiple (at baseline and after 6 weeks) allogenic feces (infusion of lean donor feces by duodenal tube) or single autologous (own) feces at baseline and after 6 weeks.
- Primary outcomeThe primary endpoint is changes in weight in relation to fecal flora composition and short chain fatty acid metabolism in fecal samples after 3, 6, 12 and 18 weeks.
- Secondary outcomeSecondary endpoints are changes in insulin resistance/fatty acid metabolism (assessed by hyperinsulinemic euglycemic clamp and stable isotope glucose infusion) and postprandial lipid metabolism (mixed meal test) at baseline and after 6 and 18 weeks. Before each mixed meal test a subcutaneous adipose tissue biopsy will be obtained to assess phosphorylation status of the insulin signalling cascade in relation to metabolic genes (perilipin3). Finally, during positioning of duodenal tube, biopsies will be taken at baseline and after 6 & 18 weeks to study small intestine epithelium composition.
- TimepointsBaseline, 3, 6, 12 and 18 weeks.
- Trial web siteN/A
- statusopen: patient inclusion
- CONTACT FOR PUBLIC QUERIESDrs. A. Vrieze
- CONTACT for SCIENTIFIC QUERIESMD. PhD. R.S. Kootte
- Sponsor/Initiator Academic Medical Center (AMC, Amsterdam)
- Funding
(Source(s) of Monetary or Material Support)
Academic Medical Center (AMC)
- PublicationsN/A
- Brief summaryObjective:
To investigate whether single vs multiple doses of fecal therapy by infusion of allogenic (lean donor feces in the bowel) or autologous (own feces) have differential effect on longterm reduction of insulin resistance, postprandrial dyslipidemia and short chain free fatty acid metabolism.

Study design:
Double blind randomized controlled single center trial.

Study Population:
Male obese patients with metabolic syndrome.

Treatment:
Patients will be randomised to one of the three treatment arms: Single (baseline) or multiple (at baseline and after 6 weeks) allogenic feces (infusion of lean donor feces by duodenal tube) or single autologous (own) feces at baseline.

Outcome measures:
The primary endpoint changes in fecal flora composition and shortchain fatty acid metabolism in fecal samples after 3, 6, 12 and 18 weeks. Secondary endpoints are changes in insulin resistance/fatty acid metabolism (assessed by hyperinsulinemic normoglycemic clamp and stable isotope glucose) and postprandrial lipidmetabolism (mixed meal test) at baseline and after 6 and 18 weeks. Finally, changes in gutregulatory hormones in plasma (leptin, adiponectin and GLP-1) will be assessed.

Sample Size:
It is estimated that a total of 45 patients (15 MS patients per treatment arm) and 30 healthy lean volunteers are need.
- Main changes (audit trail)
- RECORD18-jan-2011 - 25-feb-2012


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl